Hetrombopag API is a high-purity thrombopoietin (TPO) receptor agonist developed for the treatment of thrombocytopenia, a condition characterized by abnormally low platelet counts. It stimulates the thrombopoietin receptor (c-Mpl) on bone marrow megakaryocytes, promoting platelet production and helping reduce the risk of bleeding in patients with platelet disorders.
Hetrombopag is primarily used in the management of chronic immune thrombocytopenia (ITP) and other thrombocytopenic conditions requiring increased platelet production. It is formulated as oral tablets and is recognized for its efficacy and convenient dosing regimen.
Manufactured under WHO-GMP-certified facilities, our Hetrombopag API offers exceptional purity, stability, and consistent batch quality. Each batch is supplied with comprehensive regulatory documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), and Technical Data Sheet (TDS).
Hetrombopag API is used for the treatment of thrombocytopenia, particularly chronic immune thrombocytopenia (ITP), by increasing platelet production.
Hetrombopag activates thrombopoietin (TPO) receptors on bone marrow cells, stimulating megakaryocyte development and increasing platelet production.
Yes. We provide commercial bulk quantities with CoA, MSDS, and complete regulatory documentation.
Get Bulk Quote via WhatsApp